Subjects -> MEDICAL SCIENCES (Total: 8529 journals)
    - ALLERGOLOGY AND IMMUNOLOGY (216 journals)
    - ANAESTHESIOLOGY (120 journals)
    - CARDIOVASCULAR DISEASES (332 journals)
    - CHIROPRACTIC, HOMEOPATHY, OSTEOPATHY (21 journals)
    - COMMUNICABLE DISEASES, EPIDEMIOLOGY (231 journals)
    - DENTISTRY (292 journals)
    - DERMATOLOGY AND VENEREOLOGY (164 journals)
    - EMERGENCY AND INTENSIVE CRITICAL CARE (120 journals)
    - ENDOCRINOLOGY (150 journals)
    - FORENSIC SCIENCES (41 journals)
    - GASTROENTEROLOGY AND HEPATOLOGY (186 journals)
    - GERONTOLOGY AND GERIATRICS (136 journals)
    - HEMATOLOGY (155 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (167 journals)
    - LABORATORY AND EXPERIMENTAL MEDICINE (99 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2342 journals)
    - NURSES AND NURSING (362 journals)
    - OBSTETRICS AND GYNECOLOGY (207 journals)
    - ONCOLOGY (381 journals)
    - OPHTHALMOLOGY AND OPTOMETRY (138 journals)
    - ORTHOPEDICS AND TRAUMATOLOGY (167 journals)
    - OTORHINOLARYNGOLOGY (82 journals)
    - PATHOLOGY (98 journals)
    - PEDIATRICS (273 journals)
    - PHYSICAL MEDICINE AND REHABILITATION (157 journals)
    - PSYCHIATRY AND NEUROLOGY (822 journals)
    - RADIOLOGY AND NUCLEAR MEDICINE (192 journals)
    - RESPIRATORY DISEASES (103 journals)
    - RHEUMATOLOGY (78 journals)
    - SPORTS MEDICINE (81 journals)
    - SURGERY (401 journals)
    - UROLOGY, NEPHROLOGY AND ANDROLOGY (153 journals)

ALLERGOLOGY AND IMMUNOLOGY (216 journals)                  1 2 | Last

Showing 1 - 200 of 216 Journals sorted alphabetically
Acta Microbiologica et Immunologica Hungarica     Full-text available via subscription   (Followers: 5)
Advances in Immunology     Full-text available via subscription   (Followers: 39)
AIDS Research and Therapy     Open Access   (Followers: 15)
Alergologia Polska : Polish Journal of Allergology     Full-text available via subscription   (Followers: 2)
Allergies     Open Access   (Followers: 2)
Allergo Journal     Full-text available via subscription   (Followers: 2)
Allergo Journal International     Hybrid Journal   (Followers: 2)
Allergologia et Immunopathologia     Full-text available via subscription   (Followers: 1)
Allergology International     Open Access   (Followers: 5)
Allergy     Hybrid Journal   (Followers: 50)
Allergy & Rhinology     Open Access   (Followers: 4)
Allergy and Asthma Proceedings     Full-text available via subscription   (Followers: 14)
Allergy, Asthma and Clinical Immunology     Open Access   (Followers: 26)
American Journal of Epidemiology     Hybrid Journal   (Followers: 220)
American Journal of Immunology     Open Access   (Followers: 23)
American Journal of Preventive Medicine     Hybrid Journal   (Followers: 29)
American Journal of Reproductive Immunology     Hybrid Journal   (Followers: 6)
American Journal of Rhinology and Allergy     Hybrid Journal   (Followers: 9)
Annals of Allergy, Asthma and Immunology     Hybrid Journal   (Followers: 14)
Annals of Allergy, Asthma, and Immunology     Hybrid Journal  
Annual Review of Immunology     Full-text available via subscription   (Followers: 51)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry     Hybrid Journal   (Followers: 5)
Applied Immunohistochemistry & Molecular Morphology     Hybrid Journal   (Followers: 17)
Archives of Asthma, Allergy and Immunology     Open Access  
Archivum Immunologiae et Therapiae Experimentalis     Hybrid Journal   (Followers: 2)
Autoimmune Diseases     Open Access   (Followers: 3)
Autoimmunity     Hybrid Journal   (Followers: 9)
Autoimmunity Highlights     Open Access   (Followers: 2)
Autoimmunity Reviews     Hybrid Journal   (Followers: 3)
BMC Immunology     Open Access   (Followers: 11)
Cancer Immunology, Immunotherapy     Hybrid Journal   (Followers: 22)
Case Reports in Immunology     Open Access   (Followers: 6)
Cellular & Molecular Immunology     Hybrid Journal   (Followers: 15)
Cellular Immunology     Hybrid Journal   (Followers: 31)
Chronic Diseases and Injuries in Canada     Free   (Followers: 1)
Clinica Chimica Acta     Hybrid Journal   (Followers: 28)
Clinical & Experimental Allergy     Hybrid Journal   (Followers: 7)
Clinical & Experimental Allergy Reviews     Hybrid Journal   (Followers: 1)
Clinical & Experimental Immunology     Hybrid Journal   (Followers: 18)
Clinical & Translational Immunology     Open Access   (Followers: 8)
Clinical and Experimental Neuroimmunology     Hybrid Journal   (Followers: 1)
Clinical and Molecular Allergy     Open Access   (Followers: 5)
Clinical and Translational Allergy     Open Access   (Followers: 2)
Clinical Immunology     Hybrid Journal   (Followers: 25)
Clinical Immunology, Endocrine & Metabolic Drugs     Hybrid Journal  
Clinical Reviews in Allergy and Immunology     Hybrid Journal   (Followers: 12)
Comparative Immunology, Microbiology and Infectious Diseases     Hybrid Journal   (Followers: 14)
Critical Reviews in Immunology     Full-text available via subscription   (Followers: 15)
Current Allergy & Clinical Immunology     Open Access   (Followers: 8)
Current Allergy and Asthma Reports     Hybrid Journal   (Followers: 2)
Current Immunology Reviews     Hybrid Journal   (Followers: 10)
Current Opinion in Allergy and Clinical Immunology     Hybrid Journal   (Followers: 8)
Current Opinion in Immunology     Hybrid Journal   (Followers: 44)
Current Opinion in Virology     Hybrid Journal   (Followers: 1)
Current Protocols in Immunology     Hybrid Journal  
Current Treatment Options in Allergy     Hybrid Journal   (Followers: 2)
Developmental & Comparative Immunology     Hybrid Journal   (Followers: 7)
Egyptian Journal of Pediatric Allergy and Immunology     Open Access   (Followers: 2)
Emerging Infectious Diseases     Open Access   (Followers: 30)
Epidemiologic Methods     Hybrid Journal   (Followers: 4)
European Annals of Allergy and Clinical Immunology     Open Access   (Followers: 5)
European Journal of Immunology     Hybrid Journal   (Followers: 39)
European Journal of Microbiology and Immunology     Open Access   (Followers: 11)
Expert Review of Clinical Immunology     Full-text available via subscription   (Followers: 5)
Expert Review of Vaccines     Full-text available via subscription   (Followers: 4)
Food and Agricultural Immunology     Open Access   (Followers: 2)
Frontiers in Immunology     Open Access   (Followers: 20)
Future Virology     Hybrid Journal   (Followers: 8)
Genes & Immunity     Hybrid Journal   (Followers: 8)
Global Journal of Allergy     Open Access   (Followers: 1)
Handbook of Systemic Autoimmune Diseases     Full-text available via subscription   (Followers: 2)
HLA Immune Response Genetics     Hybrid Journal  
HNO Nachrichten     Full-text available via subscription  
Human Immunology     Hybrid Journal   (Followers: 18)
Human Vaccines & Immunotherapeutics     Full-text available via subscription   (Followers: 2)
Hypersensitivity     Open Access   (Followers: 1)
Immunity     Full-text available via subscription   (Followers: 66)
Immunity & Ageing     Open Access   (Followers: 10)
Immunity, Inflammation and Disease     Open Access   (Followers: 6)
Immuno-analyse & Biologie Spécialisée     Full-text available via subscription   (Followers: 2)
Immunobiology     Hybrid Journal   (Followers: 9)
Immunoendocrinology     Open Access   (Followers: 1)
Immunogenetics     Hybrid Journal   (Followers: 6)
ImmunoHorizons     Open Access  
Immunologic Research     Hybrid Journal   (Followers: 6)
Immunological Investigations: A Journal of Molecular and Cellular Immunology     Hybrid Journal   (Followers: 2)
Immunological Medicine     Open Access  
Immunological Reviews     Hybrid Journal   (Followers: 27)
Immunology     Hybrid Journal   (Followers: 38)
Immunology & Cell Biology     Hybrid Journal   (Followers: 9)
Immunology and Allergy Clinics of North America     Full-text available via subscription   (Followers: 6)
Immunology and Immunogenetic Insights     Open Access   (Followers: 5)
Immunology and Infectious Diseases     Open Access   (Followers: 9)
Immunology Innovation     Open Access   (Followers: 2)
Immunology Letters     Hybrid Journal   (Followers: 13)
Immunology, Endocrine & Metabolic Agents - Medicinal Chemistry     Hybrid Journal   (Followers: 3)
Immunome Research     Open Access   (Followers: 6)
ImmunoTargets and Therapy     Open Access   (Followers: 2)
Immunotherapy     Hybrid Journal   (Followers: 7)
Immunotoxicology of Drugs and Chemicals: an Experimental and Clinical Approach     Full-text available via subscription   (Followers: 1)
Indian Journal of Allergy, Asthma and Immunology     Open Access   (Followers: 1)
Infectious Diseases: Research and Treatment     Open Access   (Followers: 4)
Inflammation & Allergy - Drug Targets     Hybrid Journal   (Followers: 2)
Inmunología     Full-text available via subscription   (Followers: 2)
Innate Immunity     Hybrid Journal   (Followers: 7)
International Archives of Allergy and Immunology     Full-text available via subscription   (Followers: 1)
International Forum of Allergy & Rhinology     Hybrid Journal   (Followers: 4)
International Immunology     Hybrid Journal   (Followers: 3)
International Immunopharmacology     Hybrid Journal   (Followers: 2)
International Journal of Immunological Studies     Hybrid Journal   (Followers: 1)
International Journal of Immunopathology and Pharmacology     Full-text available via subscription   (Followers: 2)
International Journal of Immunotherapy and Cancer Research     Open Access   (Followers: 1)
International Journal of Infectious Diseases     Open Access   (Followers: 10)
International Journal of Virology     Open Access   (Followers: 2)
International Reviews Of Immunology     Hybrid Journal   (Followers: 4)
Internet Journal of Rheumatology and Clinical Immunology     Open Access   (Followers: 5)
Iranian Journal of Allergy, Asthma and Immunology     Open Access  
Joint Commission Journal on Quality and Patient Safety     Hybrid Journal   (Followers: 40)
Journal des Anti-infectieux     Full-text available via subscription   (Followers: 2)
Journal of Allergy & Therapy     Open Access   (Followers: 2)
Journal of Clinical & Cellular Immunology     Open Access   (Followers: 3)
Journal of Vaccines & Vaccination     Open Access   (Followers: 4)
Journal of Allergy and Clinical Immunology     Hybrid Journal   (Followers: 31)
Journal of Allergy and Clinical Immunology : In Practice     Full-text available via subscription   (Followers: 13)
Journal of Asthma Allergy Educators     Hybrid Journal   (Followers: 4)
Journal of Asthma and Allergy     Open Access   (Followers: 8)
Journal of Autoimmunity     Hybrid Journal   (Followers: 15)
Journal of Cellular Immunotherapy     Open Access   (Followers: 4)
Journal of Clinical Immunology     Hybrid Journal   (Followers: 14)
Journal of Clinical Immunology and Immunopathology Research     Open Access   (Followers: 5)
Journal of General Virology     Full-text available via subscription   (Followers: 11)
Journal of Immune Based Therapies, Vaccines and Antimicrobials     Open Access   (Followers: 2)
Journal of Immunological Methods     Hybrid Journal   (Followers: 46)
Journal of Immunological Techniques in Infectious Diseases     Hybrid Journal   (Followers: 3)
Journal of Immunology     Full-text available via subscription   (Followers: 68)
Journal of Immunology and Clinical Microbiology     Open Access   (Followers: 2)
Journal of Immunology and Regenerative Medicine     Hybrid Journal   (Followers: 1)
Journal of Immunology Research     Open Access   (Followers: 9)
Journal of Immunotherapy     Hybrid Journal   (Followers: 7)
Journal of Immunotherapy Applications     Open Access  
Journal of Immunotoxicology     Open Access   (Followers: 3)
Journal of Infection Prevention     Hybrid Journal   (Followers: 16)
Journal of Infectious Diseases and Immunity     Open Access   (Followers: 8)
Journal of Innate Immunity     Open Access   (Followers: 6)
Journal of Medical Genetics and Genomics     Open Access   (Followers: 3)
Journal of Microbiology, Immunology and Infection     Open Access   (Followers: 9)
Journal of Neuroimmunology     Hybrid Journal   (Followers: 6)
Journal of NeuroVirology     Hybrid Journal   (Followers: 1)
Journal of Reproductive Immunology     Hybrid Journal   (Followers: 2)
Journal of the Pediatric Infectious Diseases Society     Hybrid Journal   (Followers: 11)
Journal of Translational Autoimmunity     Open Access   (Followers: 2)
Journal of Vaccines and Immunology     Open Access   (Followers: 1)
Medical Immunology     Open Access   (Followers: 20)
Medical Microbiology and Immunology     Hybrid Journal   (Followers: 7)
Microbiology and Immunology     Hybrid Journal   (Followers: 10)
Molecular Immunology     Hybrid Journal   (Followers: 17)
Mucosal Immunology     Hybrid Journal   (Followers: 6)
Nature Immunology     Full-text available via subscription   (Followers: 315)
Nature Reviews Immunology     Full-text available via subscription   (Followers: 300)
Neuroimmunology and Neuroinflammation     Open Access   (Followers: 3)
NeuroImmunoModulation     Full-text available via subscription   (Followers: 2)
Neurology : Neuroimmunology & Neuroinflammation     Open Access   (Followers: 4)
npj Vaccines     Hybrid Journal  
OA Immunology     Open Access  
Ocular Immunology & Inflammation     Hybrid Journal   (Followers: 9)
OncoImmunology     Full-text available via subscription   (Followers: 3)
Open Allergy Journal     Open Access  
Open Cancer Immunology Journal     Open Access  
Open Forum Infectious Diseases     Open Access   (Followers: 4)
Open Immunology Journal     Open Access  
Open Journal of Immunology     Open Access   (Followers: 5)
Open Virology Journal     Open Access  
Oral Microbiology and Immunology     Hybrid Journal   (Followers: 1)
Papillomavirus Research     Open Access  
Parasite Immunology     Hybrid Journal   (Followers: 3)
Pediatric Allergy and Immunology     Hybrid Journal   (Followers: 38)
Perspectives in Vaccinology     Open Access   (Followers: 1)
Photodermatology, Photoimmunology & Photomedicine     Hybrid Journal   (Followers: 3)
Polish Pneumonology and Allergology     Open Access   (Followers: 1)
Procedia in Vaccinology     Open Access   (Followers: 2)
Recent Patents on Inflammation & Allergy Drug Discovery     Hybrid Journal   (Followers: 2)
Research & Reviews : A Journal of Immunology     Full-text available via subscription   (Followers: 6)
Research Journal of Allergy     Open Access   (Followers: 3)
Research Journal of Immunology     Open Access   (Followers: 3)
Results in Immunology     Open Access   (Followers: 4)
Revista Alergia México     Open Access  
Revista Portuguesa de Imunoalergologia     Open Access   (Followers: 2)
Revue Française d'Allergologie     Full-text available via subscription   (Followers: 3)
Russian Journal of Infection and Immunity     Open Access   (Followers: 20)
Scandinavian Journal of Immunology     Hybrid Journal   (Followers: 10)
Science Immunology     Full-text available via subscription   (Followers: 17)
Self/Nonself - Immune Recognition and Signaling     Full-text available via subscription   (Followers: 2)
Seminars in Immunology     Hybrid Journal   (Followers: 13)
Seminars in Immunopathology     Hybrid Journal   (Followers: 3)
Signals     Open Access   (Followers: 1)
Sinusitis     Open Access   (Followers: 1)
South East European Journal of Immunology     Open Access  
Therapeutic Advances in Vaccines     Hybrid Journal   (Followers: 1)
Therapeutic Advances in Vaccines and Immunotherapy     Open Access  
Toxicology and Environmental Health Sciences     Hybrid Journal   (Followers: 6)

        1 2 | Last

Similar Journals
Journal Cover
Papillomavirus Research
Journal Prestige (SJR): 1.128
Citation Impact (citeScore): 2
Number of Followers: 0  

  This is an Open Access Journal Open Access journal
ISSN (Online) 2405-8521
Published by Elsevier Homepage  [3204 journals]
  • Mega Hpv laboratories for cervical cancer control: Challenges and
           recommendations from a case study of Turkey

    • Abstract: Publication date: June 2019Source: Papillomavirus Research, Volume 7Author(s): Murat Gultekin, Mujdegul Zayifoglu Karaca, Irem Kucukyildiz, Selin Dundar, Bekir Keskinkilic, Murat TurkyilmazAbstractCervical cancer is the fourth most common cancer among women in the world. It is estimated that one woman dies every 2 min from cervical cancer. Nearly all cervical cancers are preventable by early detection and treatment through screening or HPV vaccination. In 2018, World Health Organization (WHO) made a global call for action toward the elimination of cervical cancer. Cervical cancer screening involves a complex organized program, which begins with a call/recall system based on personal invitation of eligible women, followed by participation in screening, and leading to diagnosis, treatment, and management as appropriate. An effective cervical screening program with high coverage is dependent on each country's infrastructure and human resource capacity. Efforts to develop an effective program is particularly challenging in low and middle income countries (LMIC) where resources are limited. For an effective strategy, Turkey redesigned the country's cervical screening program. The local call/recall system and centralized monitoring system of individual women were re-vamped with an automated evaluation system. The revised screening program includes the use of primary HPV testing with a well-defined protocol outlining the algorithms of management (i.e., screening intervals and referral), a single nationwide centralized diagnostic laboratory, and a sustainable agreement with the HPV diagnostics industry. This system allows for traceable, real-time monitoring of screening visits and specimens. Turkey reports on the first four years of this re-vamped organized program and shares lessons learnt from the implementation of this new program.
       
  • Effect of vaccination against oral HPV-16 infection in high school
           students in the city of Cali, Colombia

    • Abstract: Publication date: June 2019Source: Papillomavirus Research, Volume 7Author(s): Andres Castillo, Julio Cesar Osorio, Adrián Fernández, Fabián Méndez, Liliana Alarcón, Gabriela Arturo, Rolando Herrero, Luis Eduardo BravoAbstractIntroductionIn recent years, an association between HPV-16 and oropharyngeal cancers has been reported. Therefore, it is necessary to evaluate whether vaccination decreases the exposure of HPV-16 in the oral cavity.ObjectiveTo evaluate the effect of vaccination on oral HPV-16 infection in high school students in the city of Cali, Colombia.MethodsIn this cross-sectional study, HPV-16 DNA was detected in samples from the oral cavity and throat of 1,784 high school students of both genders, aged 14–17 years old, in 21 schools in the city of Cali, Colombia. The number in vaccinated girls were 944 vs., 95 unvaccinated girls and 745 unvaccinated boys.ResultsThe HPV exposure percentages were: 0.7% in vaccinated girls, 3.2% in unvaccinated girls and 2.3% in unvaccinated boys. The odds ratio (OR) of detection of HPV-16 in vaccinated versus unvaccinated students was 0.28 (95% CI: 0.07–0.88), representing a 72% reduction in HPV-16 detection in students immunized with two doses. The odds of detection of HPV-16 in unvaccinated male students were 3.6 times those of vaccinated girls (OR = 3.6, 95% CI: 1.21–12.81) and increased to almost eight-fold in boys who had initiated sexual activity (OR = 7.74, 95% CI: 1.53–75.09).ConclusionsHPV vaccination was associated with the reduction of HPV-16 exposure percentages in the oral and oropharyngeal cavity.
       
  • Discovery, characterisation and genomic variation of six novel
           Gammapapillomavirus types from penile swabs in South Africa

    • Abstract: Publication date: June 2019Source: Papillomavirus Research, Volume 7Author(s): Alltalents T. Murahwa, Tracy L. Meiring, Zizipho Z.A. Mbulawa, Anna-Lise WilliamsonAbstractSix novel human papillomaviruses from penile swabs were characterised. Multiple full genome clones for each novel type were generated, and complete genome sizes were: HPV211 (7253bp), HPV212 (7208bp), HPV213 (7096bp), HPV214 (7357), HPV215 (7186bp) and HPV216 (7233bp). Phylogenetically the novel papillomaviruses all clustered with Gammapapillomaviruses: HPV211 is most closely related to HPV168 (72% identity in the L1 nucleotide sequence) of the Gamma-8 species, HPV212 is most closely related to HPV144 (82.9%) of the Gamma-17 species, HPV213 is most closely related to HPV153 (71.8%) of the Gamma-13 species, HPV214 is most closely related to HPV103 (75.3%) of the Gamma-6 species, HPV215 and HPV216 are most closely related to HPV129 (76.8% and 79.2% respectively) of the Gamma-9 species. The novel HPV types demonstrated the classical genomic organisation of Gammapapillomavirusess, with seven open reading frames (ORFs) encoding five early (E1, E2, E4, E6 and E7) and two late (L1 and L2) proteins. Typical of Gammapapillomavirusess the novel types all lacked the E5 ORF and HPV214 also lacked the E6 ORF. HPV212 had nine unique variants, HPV213 had five and HPV215 had four variants. Conserved domains observed among the novel types are the Zinc finger Binding Domain and PDZ domains. A retinoblastoma binding domain (pRB) binding domain in E7 protein was additionally identified in HPV214. This study expands the knowledge of the rapidly growing Gammapapillomavirus genus.
       
  • Human Papillomavirus infection in senegalese female sex workers

    • Abstract: Publication date: June 2019Source: Papillomavirus Research, Volume 7Author(s): Halimatou Diop-Ndiaye, Kaylin Beiter, Tarik Gheit, Aissatou Sow Ndoye, Aboubacry Dramé, Sandrine McKay-Chopin, Massimo Tommasino, Cheikh Saad Bouh Boye, Bakary Sylla, Coumba Touré KaneAbstractObjectivesSeveral studies have documented the HPV genotypes in the Senegalese general population. The objective was to explore the HPV genotype distribution in Senegalese FSWs in order to assess the potential relevance of currently-available vaccines.MethodsVaginal swabs samples collected as part of the National Integrated Biological and Behavioral Survey in 14 regions throughout the country were randomly selected for HPV testing using bead-based multiplex genotyping (TS-MPG).ResultsAmong the 436 FSW samples analyzed, the overall HPV prevalence was 79.8% (N = 348), with 70.1% (N = 244) cases presenting as multiple infections. High Risk HPV genotypes affecting at least 10% of FSWs included in order of decreasing frequency: 52, 16, 35, 51, 33, 31, 18, and 45. Sixty-seven (15.4%) FSWs were HIV positive and they were significantly more affected by HPV (94% vs 77%; p 
       
  • Viral genome integration of canine papillomavirus 16

    • Abstract: Publication date: June 2019Source: Papillomavirus Research, Volume 7Author(s): Jennifer Luff, Michelle Mader, Peter Rowland, Monica Britton, Joseph Fass, Hang YuanAbstractPapillomaviruses infect humans and animals, most often causing benign proliferations on skin or mucosal surfaces. Rarely, these infections persist and progress to cancer. In humans, this transformation most often occurs with high-risk papillomaviruses, where viral integration is a critical event in carcinogenesis. The first aim of this study was to sequence the viral genome of canine papillomavirus (CPV) 16 from a pigmented viral plaque that progressed to metastatic squamous cell carcinoma in a dog. The second aim was to characterize multiple viral genomic deletions and translocations as well as host integration sites. The full viral genome was identified using a combination of PCR and high throughput sequencing. CPV16 is most closely related to chipapillomaviruses CPV4, CPV9, and CPV12 and we propose CPV16 be classified as a chipapillomavirus. Assembly of the full viral genome enabled identification of deletion of portions of the E1 and E2/E4 genes and two viral translocations within the squamous cell carcinoma. Genome walking was performed which identified four sites of viral integration into the host genome. This is the first description of integration of a canine papillomavirus into the host genome, raising the possibility that CPV16 may be a potential canine high-risk papillomavirus type.
       
  • Whole tissue cervical mapping of HPV infection: Molecular evidence for
           focal latent HPV infection in humans

    • Abstract: Publication date: June 2019Source: Papillomavirus Research, Volume 7Author(s): Anne Hammer, Maurits NC de Koning, Jan Blaakaer, Torben Steiniche, John Doorbar, Heather Griffin, Else Mejlgaard, Hans Svanholm, Wim GV Quint, Patti E. GravittAbstractIn this study, we aimed to provide molecular evidence of HPV latency in humans and discuss potential challenges of conducting studies on latency. We analyzed the entire cervix of two women who underwent hysterectomy unrelated to cervical abnormality. The cervices were sectioned into 242 and 186 sets respectively, and each set was tested separately for HPV using the SPF10-PCR-DEIA-LiPA25 system. To identify whether there was any evidence of transforming or productive infection, we used the biomarkers E4 and P16INK4a to stain slides immediately adjacent to HPV-positive sections. HPV was detected in both cervices. In patient 1, 1/242 sets was positive for HPV31. In patient 2, 13/186 sets were positive for HPV18 and 1/186 was positive for HPV53. The infection was very focal in both patients, and there was no sign of a transforming or productive infection, as evaluated by the markers E4 and P16INK4a. Had we only analyzed one set from each block, the probability of detecting the infection would have been 32.3% and 2%, respectively.Our findings support the idea that HPV may be able to establish latency in the human cervix; however, the risk associated with a latent HPV infection remains unclear.
       
  • Two-dose recommendation for Human Papillomavirus vaccine can be extended
           up to 18 years – updated evidence from Indian follow-up cohort study

    • Abstract: Publication date: June 2019Source: Papillomavirus Research, Volume 7Author(s): Partha Basu, Richard Muwonge, Neerja Bhatla, Bhagwan M. Nene, Smita Joshi, Pulikottil O. Esmy, Usha Rani Reddy Poli, Geeta Joshi, Yogesh Verma, Eric Zomawia, Surendra S. Shastri, Sharmila Pimple, Devasena Anantharaman, Priya R. Prabhu, Sanjay Hingmire, Catherine Sauvaget, Eric Lucas, Michael Pawlita, Tarik Gheit, Kasturi JayantAbstractEarlier publication from the ongoing multi-centric study of the International Agency for Research on Cancer to evaluate less than three doses of the quadrivalent Human Papillomavirus (HPV) vaccine in India amongst unmarried girls demonstrated non-inferior total antibody titres, neutralizing antibody titres and antibody avidity in 2-dose recipients compared to 3-dose recipients at 15–18 years of age (Bhatla et al., 2018) [7].The number of participants recruited at 15–18 years of age was 1515 and 1795 in the 3-dose and the 2-dose groups respectively. At a median follow-up of 7 years, incident HPV 16/18 infections were detected in 1.6% women receiving two doses and 0.8% women receiving three doses at 15–18 years. Frequency of incident infection was 7.0% in the age- and site-matched unvaccinated women (N = 1484). No persistent infection from HPV 16 was observed in the 2- or 3-dose recipients and one (0.2%) persistent HPV 18 infection was documented, each in the 3-dose and 2-dose cohorts. Among the unvaccinated women, the frequency of HPV 16/18 persistent infection was 1.7%.The protection offered by two doses of quadrivalent HPV vaccine against incident and persistent infections in recipients at 15–18 years is comparable to that seen in 3-dose recipients at 15–18 years.
       
  • Human papillomavirus 16 sub-lineage dispersal and cervical cancer risk
           worldwide: Whole viral genome sequences from 7116 HPV16-positive women

    • Abstract: Publication date: June 2019Source: Papillomavirus Research, Volume 7Author(s): Gary M. Clifford, Vanessa Tenet, Damien Georges, Laia Alemany, Miquel Angel Pavón, Zigui Chen, Meredith Yeager, Michael Cullen, Joseph F. Boland, Sara Bass, Mia Steinberg, Tina Raine-Bennett, Thomas Lorey, Nicolas Wentzensen, Joan Walker, Rosemary Zuna, Mark Schiffman, Lisa MirabelloAbstractBackgroundHuman papillomavirus (HPV)16 can be separated into genetic sub-lineages (A1–4, B1–4, C1–4, D1–4) which may have differential cervical cancer risk.MethodsA next-generation sequencing assay was used to whole-genome sequence 7116 HPV16-positive cervical samples from well-characterised international epidemiological studies, including 2076 controls, 1878 squamous cell carcinoma (SCC) and 186 adenocarcinoma/adenosquamous cell carcinoma (ADC), and to assign HPV16 sub-lineage. Logistic regression was used to estimate region-stratified country-adjusted odds ratios (OR) and 95%CI.ResultsA1 was the most globally widespread sub-lineage, with others showing stronger regional specificity (A3 and A4 for East Asia, B1–4 and C1–4 for Africa, D2 for the Americas, B4, C4 and D4 for North Africa). Increased cancer risks versus A1 were seen for A3, A4 and D (sub)lineages in regions where they were common: A3 in East Asia (OR=2.2, 95%CI:1.0–4.7); A4 in East Asia (6.6, 3.1–14.1) and North America (3.8, 1.7–8.3); and D in North (6.2, 4.1–9.3) and South/Central America (2.2, 0.8–5.7), where D lineages were also more frequent in ADC than SCC (3.2, 1.5–6.5; 12.1, 5.7–25.6, respectively).ConclusionsHPV16 genetic variation can strongly influence cervical cancer risk. However, burden of cervical cancer attributable to different sub-lineages worldwide is largely driven by historical HPV16 sub-lineage dispersal.
       
  • Obituary Peter Snijders

    • Abstract: Publication date: June 2019Source: Papillomavirus Research, Volume 7Author(s): Chris J.L.M. Meijer, On behalf of the HPV Team
       
  • “We brought our culture here with us”: A qualitative study of
           perceptions of HPV vaccine and vaccine uptake among East African immigrant
           mothers

    • Abstract: Publication date: June 2019Source: Papillomavirus Research, Volume 7Author(s): Linda K. Ko, Victoria M. Taylor, Farah Bille Mohamed, H. Hoai Do, Fanaye A. Gebeyaw, Anisa Ibrahim, Ahmed A. Ali, Rachel L. WinerAbstractBackgroundHPV vaccine studies in East African communities are few and focus mainly on Somali women and girls. We examined how HPV vaccine perceptions and uptake are shaped among Somali, Ethiopian, and Eritrean mothers.MethodsWe convened three focus groups in Somali, Amharic, and Tigrinya with mothers of 11–17 year old children. The Socio-Context Framework (social, cultural, and religious factors) and Andersen's Behavioral Model (predisposing, enabling, and need for care factors) informed question development.ResultsNegative vaccine perceptions, lack of HPV vaccine knowledge, and concerns about side effects emerged as predisposing factors. Having a provider who engages parents on HPV vaccination and takes responsibility for vaccine-related risks emerged as enabling factors. Availability of vaccine information resources (e.g., person-to-person, word of mouth education for parents) were also enabling factors. Need for care factors included having comprehensive vaccine information, strong recommendation from a doctor, and validation from a co-ethnic medical professional. Women exerted strong social influence on vaccine uptake (social), had concerns about pork gelatin in vaccines (religious), and felt discussions about sex with children were culturally unacceptable (cultural).ConclusionStrategies for vaccine uptake among East African immigrants need to address factors that shape HPV vaccine perceptions for adolescents, caregivers, and providers.
       
  • Variants in immune-related genes and genital HPV 16 persistence in men

    • Abstract: Publication date: June 2019Source: Papillomavirus Research, Volume 7Author(s): Bigyan Mainali, Matthew B. Schabath, Staci L. Sudenga, Yuanfan Ye, Howard W. Wiener, Luisa L. Villa, Anna R. Giuliano, Sadeep ShresthaAbstractObjectivesWhile most human papillomavirus (HPV) infection clears on its own, persistent HPV infection can cause genital warts and anal, penile and oropharyngeal cancers in men. We conducted genetic analysis in a sub-cohort of the HPV infection in men (HIM) study to test the hypothesis that differences in host genes influence HPV persistence in men.MethodsBaseline and longitudinal genital HPV status at the genitals was measured every 6-months using the Linear Array assay amplified HPV L1 gene fragment using the PGMY09/11 L1 consensus primer system. DNA was extracted from peripheral blood and single nucleotide polymorphisms (SNPs) in the customized genome-wide genotyping array, the “TxArray,” were examined using logistic regression in a case-control study design to assess the association with HPV16 persistence/clearance.ResultsOf the total of 737,742 autosomal SNPs in the array, 605,885 passed basic quality control and were examined between 40 men (cases) with > 18 months persistent genital HPV 16 infection vs. 151 controls who were HPV 16-positive, but whose infections cleared in
       
  • Long-term survival and swallowing outcomes in advanced stage oropharyngeal
           squamous cell carcinomas

    • Abstract: Publication date: June 2019Source: Papillomavirus Research, Volume 7Author(s): Jessica M. Clark, Emma M. Holmes, Daniel A. O’Connell, Jeffrey Harris, Hadi Seikaly, Vincent L. BironAbstractBackgroundThere is a paucity of studies reporting long-term survival outcomes for HPV/p16 positive oropharyngeal squamous cell carcinoma (OPSCC). This study aims to compare long-term outcomes of advanced stage p16 positive and negative OPSCCs, treated by surgical and non-surgical modalities.MethodsOPSCC patients from 1998 to 2012 were identified through a prospectively collected cancer registry. P16 immunohistochemistry was used as a surrogate marker for HPV-OPSCC. Overall survival (OS) and aspiration free survival (AFS) comparisons were made between patients treated with chemoradiation (CRT) versus primary surgery and radiation/chemoradiation (S+RT/CRT) at 5, 10 and 15 years post-treatment.ResultsA total of 319 patients were included. P16 positive patients and non-smokers had significantly higher long-term (5, 10 and 15-year) OS. Smokers and p16 negative patients treated with S+RT/CRT had improved long-term OS compared to patients who received CRT. Smokers and p16 negative patients had lower long-term AFS. Multivariate analysis showed improved OS was associated with p16 positivity (HR 0.42, 0.28–0.61) and surgery (HR 0.47, 0.32–0.69), whereas lower OS was associated with ECOG ≥ 2 (HR 2.46, 1.61–3.77), smoking (HR 2.37, 1.41–3.99) and higher stage (HR 1.68, 1.05–2.68).ConclusionsIn smokers and p16-negative OPSCC patients, primary surgery may be associated with improved long-term survival and dysphagia-related outcomes.
       
  • Malignant transformation of canine oral papillomavirus (CPV1)-associated
           papillomas in dogs: An emerging concern'

    • Abstract: Publication date: December 2018Source: Papillomavirus Research, Volume 6Author(s): Tuddow Thaiwong, Dodd G. Sledge, Annabel G. Wise, Katherine Olstad, Roger K. Maes, Matti KiupelCanine oral papillomavirus (CPV1, also known as COPV), the most common cause of non-neoplastic papillomas, has not been shown to cause squamous cell carcinomas (SCC). Furthermore, malignant transformation of benign papillomas to SCC has only been reported in a single group of dogs with severe combined immunodeficiency infected with CPV2. Here, we report a series of 7 dogs with benign CPV1-associated papillomas with histologic evidence of CPV1 causing malignant transformation to carcinoma in situ and ultimately SCC. Expression of p53 and p16 proteins in CPV1-infected cells within the benign papillomas and lesions that progressed into SCC also supported an association between papillomavirus and malignant transformation. Moreover, our retrospective analysis indicated that while there have been increased numbers of viral papillomas with malignant transformation, the number of annually diagnosed canine viral papillomas has remained constant over the past decade in our laboratory. We speculate that either an altered host immunity from increased usage of immunosuppressive drugs or changing environmental factors, e.g. increase exposure to UV radiation, may cause an increased oncogenic potential of this “low-risk” virus. This study aims to raise awareness of the malignant potential of CPV1 and to encourage further investigations into the cause of this suspected change in its oncogenic potential.Graphical abstractfx1
       
  • Performance of clinical screening algorithms comprising point-of-care
           HPV-DNA testing using self-collected vaginal specimens, and visual
           inspection of the cervix with acetic acid, for the detection of underlying
           high-grade squamous intraepithelial lesions in Papua New Guinea

    • Abstract: Publication date: December 2018Source: Papillomavirus Research, Volume 6Author(s): Pamela J. Toliman, John M. Kaldor, Steven G. Badman, Josephine Gabuzzi, Selina Silim, Antonia Kumbia, Benny Kombuk, Zure Kombati, Gloria Munnull, Rebecca Guy, Lisa M. Vallely, Angela Kelly-Hanku, Handan Wand, Claire Ryan, Grace Tan, Julia Brotherton, Marion Saville, Glen D.L. Mola, Suzanne M. Garland, Sepehr N. TabriziAbstractThe performance of different clinical screening algorithms comprising point-of-care HPV-DNA testing using self-collected vaginal (‘V’) specimens, and visual inspection of the cervix with acetic acid (VIA) was evaluated in Papua New Guinea.Women aged 30–59 years provided V specimens that were tested at point-of-care using the Xpert HPV Test (Cepheid, Sunnyvale, CA). A clinician-collected cervical (‘C’) specimen was then collected for point-of-care Xpert testing, and liquid-based cytology (LBC). Following this, VIA examination was conducted, blind to HPV test results, and ablative cervical cryotherapy provided if indicated. Detection of high-grade squamous intraepithelial lesion (HSIL) by LBC was the reference standard used to evaluate clinical screening algorithms.Of 1005 women, 36 had HSIL+. Xpert HPV Test performance using V specimens (sensitivity 91.7%, specificity 87.0%, PPV 34.0%, NPV 99.3%) was superior to VIA examination alone (51.5%, 81.4%, 17.5%, 95.6% respectively) in predicting underlying HSIL+. A screening algorithm comprising V specimen HPV testing followed by VIA examination had low sensitivity (45.5%) but comparable specificity, PPV and NPV to HPV testing alone (96.3%, 45.5%, 96.3% respectively).A ‘test-and-treat’ screening algorithm based on point-of-care HPV testing of V specimens had superior performance compared with either VIA examination alone, or a combined screening algorithm comprising HPV testing plus VIA.
       
  • HPV16 viral characteristics in primary, recurrent and metastatic vulvar
           carcinoma

    • Abstract: Publication date: December 2018Source: Papillomavirus Research, Volume 6Author(s): Gabriella Lillsunde Larsson, Malin Kaliff, Bengt Sorbe, Gisela Helenius, Mats G. KarlssonAbstractVulvar carcinoma is the fourth most common gynecological malignancy. Two separate carcinogenic pathways are suggested, where one is associated with the human papillomavirus (HPV) and HPV16 the most common genotype.The aim of this study was to evaluate HPV-markers in a set of primary tumors, metastases and recurrent lesions of vulvar squamous cell carcinomas (VSCC). Ten HPV16-positive VSCC with metastatic regional lymph nodes, distant lymphoid/hematogenous metastases or local recurrent lesions were investigated for HPV genotype, HPV16 variant, HPV16 viral load, HPV16 integration and HPV16 E2BS3 and 4 methylation.In all 10 analyzed case series, the same HPV genotype (HPV16), HPV16 variant and level of viral load were detected in all lesions within a patient case. Primary tumors with a high E2/E6 ratio were found to have fewer vulvar recurrences and/or metastases after diagnosis and treatment. Also, a significantly lower viral load was evident in regional lymph nodes compared to primary tumors.The data presented strengthens the evidence for a clonal HPV-induced pathway for vulvar carcinoma
       
  • Human papillomavirus in head and neck squamous cell carcinomas in a South
           African cohort

    • Abstract: Publication date: December 2018Source: Papillomavirus Research, Volume 6Author(s): Tumelo R. Sekee, Felicity J. Burt, Dominique Goedhals, Jacqueline Goedhals, Yuri Munsamy, Riaz Y. SeedatAbstractBackgroundMost tumours of the head and neck are attributable to smoking and alcohol use, but an increasing proportion of head and neck tumours are caused by human papillomaviruses (HPVs). The aim of this study was to use in house molecular assays to detect and genotype HPV in biopsies from patients with histologically confirmed head and neck squamous cell carcinomas. In addition, the results were compared with p16 immunohistochemistry staining, which has been described as a potential marker for HPV infection.MethodsBiopsies of squamous cell carcinomas of the oropharynx, nasopharynx, larynx and hypopharynx from 112 South African patients were screened using three PCR assays targeting the L1 and E6 regions of HPV and p16 immunohistochemical staining.Results and conclusionHPV was identified in 7 (6.3%) tumours, while 22 (19.6%) had positive p16 immunohistochemical staining. There was concordance between the results obtained using the three PCR assays. There was substantial agreement between the results of molecular tests and p16 immunohistochemistry for hypopharyngeal carcinomas, but only fair agreement for laryngeal and oropharyngeal carcinomas.
       
  • Single type infection of human papillomavirus as a cause for high-grade
           cervical intraepithelial neoplasia and invasive cancer in Japan

    • Abstract: Publication date: December 2018Source: Papillomavirus Research, Volume 6Author(s): Jinichi Sakamoto, Shoji Kamiura, Kaori Okayama, Mitsuaki Okodo, Takeo Shibata, Yasuhiro Osaka, Satoko Fujita, Emi Takata, Hiroaki Takagi, Masahiro Takakura, Toshiyuki SasagawaAbstractTo elucidate oncogenic human papilloma virus (HPV) types in Japan, HPV genotyping was performed in 1526 cervical intraepithelial neoplasia (CIN) and 371 invasive cervical cancer (ICC) patients with the novel Genosearch-31+5 HPV test. The HPV-positive rates were 89.3% and 90.8% in CIN and ICC. Regarding single-type infections, 13 internationally recognized high-risk (13HR) types excluding HPV 35, and probably HR HPV 53, 67, 69, and 70 were identified in ICC, suggesting that all these types may be oncogenic. HPV16 and 18 were identified in both SCC and adenocarcinoma (ADC). HPV HPV52, 31 and 58 (alpha-9) were predominantly detected in SCC, whereas HPV 18, 45, 39 and 59 (alpha-7) were in ADC. The prevalence of HPV 18 in SCC significantly decreased with increasing age of patients, whereas the opposite trend was observed in the other HR types. HPV18 is likely to induce SCC rapidly. All ICC cases aged 20–29 were positive for HPV 16 or 18, suggesting that present HPV 16, 18 vaccines may be quite effective to prevent ICC in young women.
       
  • Human papillomavirus genotype and prognosis of cervical cancer: Favorable
           survival of patients with HPV16-positive tumors

    • Abstract: Publication date: December 2018Source: Papillomavirus Research, Volume 6Author(s): Mamiko Onuki, Koji Matsumoto, Yuri Tenjimbayashi, Nobutaka Tasaka, Azusa Akiyama, Manabu Sakurai, Takeo Minaguchi, Akinori Oki, Toyomi Satoh, Hiroyuki YoshikawaAbstractThe prognostic impact of human papillomavirus (HPV) type on invasive cervical cancer (ICC) was analyzed for 137 women treated for ICC at a single institution between 1999 and 2007. The study subjects were divided into three groups according to HPV genotype: HPV16-positive (n = 59), HPV18-positive (n = 33), and HPV16/18-negative ICC (non-HPV16/18, n = 45). The median follow-up time was 102.5 months (range, 5–179). The 10-year overall survival (10y-OS) rates in women with FIGO stage I/II disease were similar among HPV genotypes: 94.7% for HPV16 (n = 39), 95.2% for HPV18 (n = 26), and 96.4% for non-HPV16/18 (n = 29). However, the 10y-OS rates in women with FIGO stage III/IV tumors were 73.7% for HPV16 (n = 20), 45.7% for HPV18 (n = 7), and 35.7% for other types (n = 16), with significantly higher survival in HPV16-positive compared with HPV16-negative ICC (10y-OS; 73.7% vs. 39.5%, P = 0.04). This difference in FIGO stage III/IV tumors remained significant after adjusting for age and histology (hazard ratio 0.30, 95% confidence interval 0.09–0.86, P = 0.02). These results suggest that detection of HPV16 DNA may be associated with a favorable prognosis in patients with FIGO stage III/IV ICC. Given that most women with FIGO stage III/IV tumors received concurrent chemoradiotherapy, this finding may imply that HPV16-positive tumors are more chemoradiosensitive.
       
  • Development and interlaboratory agreement of real-time PCR for HPV16
           quantification in liquid-based cervical samples

    • Abstract: Publication date: December 2018Source: Papillomavirus Research, Volume 6Author(s): David Guenat, Véronique Dalstein, Frédéric Mauny, Maëlle Saunier, Jenny Briolat, Christine Clavel, Didier Riethmuller, Christiane Mougin, Jean-Luc PrétetAbstractHigh risk HPV infection is the necessary cause for the development of precancerous and cancerous lesions of the cervix. Among HPV, HPV16 represents the most carcinogenic type. Since the determination of HPV16 DNA load could be clinically useful, we assessed quantitative real-time PCR targeting E6HPV16 and albumin genes on two different platforms. Series of SiHa cells diluted in PreservCyt were used to assess repeatability and reproducibility of two in-house real-time PCR techniques run in two different laboratories to determine HPV16 load. Furthermore, 97 HPV16 positive cervical samples were evaluated to estimate inter-center variability using Bland-Alman plots. As a whole, both techniques presented coefficients of variation for HPV16 load measurement similar to those established for other virus quantification with commercial kits. Moreover, the two real-time PCR techniques showed a very good agreement for HPV16 load calculation. Finally, we emphasize that robust HPV16 DNA quantification requires normalization of viral load by the cell number.
       
  • Oncogenic human papillomavirus infection and genotypes characterization
           among sexually active women in Tenkodogo at Burkina Faso, West Africa

    • Abstract: Publication date: December 2018Source: Papillomavirus Research, Volume 6Author(s): Rogomenoma Alice Ouedraogo, Théodora Mahoukèdè Zohoncon, Sindimalgdé Patricia Guigma, Ina Marie Angèle Traore, Abdoul Karim Ouattara, Marie Ouedraogo, Florencia Wendkuuni Djigma, Dorcas Obiri-Yeboah, Charlemagne Ouedraogo, Jacques SimporeAbstractObjectiveThis study was conducted to determine the prevalence and distribution of high-risk human papillomavirus (HR-HPV) genotypes among sexually active women in Tenkodogo, Burkina Faso.MethodsAmong 131 sexually active women attending the Tenkodogo Urban Medical Center, endocervical samples were collected prior to screening for precancerous lesions. After viral DNA extraction, fourteen HR-HPV genotypes were characterized by real-time multiplex PCR in these cervical samples.ResultsThe mean age was 35.5 ± 9.5 years. Of the 131 women, 45 were infected with at least one HR-HPV genotype. The prevalence of HR-HPV infection among these women was 34.4%. Among the 45 oncogenic HPV-infected women, single HR-HPV genotype was found in 55.6% while 44.4% were infected with more than one HR-HPV genotype. The most frequent genotypes were HPV56 (36.5%), HPV66 (36.5%).ConclusionTenkodogo women included in this study had a higher prevalence of HPV 56, HPV 66. A larger study with a more representative sample would therefore be needed to determine predominant oncogenic genotypes in the subregion and especially in cancer cases.
       
  • Anogenital human papillomavirus virus DNA and sustained response to the
           quadrivalent HPV vaccine in women living with HIV-1

    • Abstract: Publication date: December 2018Source: Papillomavirus Research, Volume 6Author(s): Michelle S. Cespedes, Minhee Kang, Erna Milunka Kojic, Triin Umbleja, Catherine Godfrey, Jennifer Y. Webster-Cyriaque, Reena Masih, Cynthia Firnhaber, Beatriz Grinsztejn, Alfred Saah, Susan Cu-Uvin, Judith A. AbergAbstractObjectivesPeople living with HIV have increased Human Papillomavirus (HPV) related lesions and malignancies. We describe HPV DNA recovered from the cervix and anal canal, explore the effect of vaccination on HPV detection, and examine the durability of vaccine titers in women living with HIV-1 who were vaccinated with the quadrivalent HPV vaccine.MethodsAIDS Clinical Trials Group A5240 was a prospective study of the quadrivalent HPV (qHPV) vaccine in 315 HIV-1 infected women in three CD4 strata (A:>350, B; 201–350, C: ≤200 cells/mm3). Vaccine was administered at entry, week 8 and week 24. Cervical and anal HPV DNA specimens were collected at baseline, weeks 28 and 52; serum for antibody testing was obtained at baseline, weeks 28 and 72.ResultsVaccine antibody titers decreased across all four HPV types at week 72 compared to week 28. Lower proportions of sustained seropositivity were observed in women with lower CD4 counts for all four vaccine types, with the lowest titers for HPV 18. Despite the decrease, the geometric mean titer levels were above the seroconversion cut-off levels for all types except HPV 18 in the lowest CD4 stratum. Of the 174 participants who had a negative baseline HPV 16 antibody and developed antibody response at week 28, 95%, 88%, and 86% retained seropositivity at week 72 in strata A, B, and C respectively. Lower antibody retention was observed in women with CD4  350 (p = 0.016). Anal HPV detection was more prevalent compared to cervical detection at all visits. Among high risk types, type 52, 31, 16, 18 and 51 were the most common in the cervical compartment, while types 16, 35, 18, and 51 were the most prevalent in the anal canal at baseline (listed in the order of prevalence). Later detection of HPV not present at baseline was uncommon in either compartment. Serial recovery of HPV over time was more commonly observed in the anal canal.ConclusionThe qHPV vaccine elicits durable titer response above the seroconversion cut-off levels in HIV-infected women. However, the titer levels were substantially lower by Week 72, most noticeably in type 18. HPV DNA was detected more frequently in the anal canal. Detection of non-vaccine high risk HPV suggests a role for the nonavalent vaccine.
       
  • A delayed dose of quadrivalent human papillomavirus vaccine demonstrates
           immune memory in HIV-1-infected men

    • Abstract: Publication date: December 2018Source: Papillomavirus Research, Volume 6Author(s): G.B. Ellsworth, S.Y. Lensing, C.B. Ogilvie, J.Y. Lee, S.E. Goldstone, J.M. Berry-Lawhorn, N. Jay, E.A. Stier, J.S. Logan, M.H. Einstein, A. Saah, R.T. Mitsuyasu, D. Aboulafia, J.M. Palefsky, T.J. Wilkin
       
  • Differential misclassification between self-reported status and official
           HPV vaccination records in Japan: Implications for evaluating vaccine
           safety and effectiveness

    • Abstract: Publication date: December 2018Source: Papillomavirus Research, Volume 6Author(s): Manako Yamaguchi, Masayuki Sekine, Risa Kudo, Sosuke Adachi, Yutaka Ueda, Etsuko Miyagi, Megumi Hara, Sharon J.B. Hanley, Takayuki EnomotoAbstractJapan has no national vaccine registry and approximately 1700 municipalities manage the immunization records independently. In June 2013, proactive recommendations for the human papillomavirus (HPV) vaccine were suspended after unconfirmed reports of adverse events following immunization in the media, despite no vaccine safety signal having been raised. Furthermore, studies assessing HPV vaccine safety and effectiveness published post suspension are predominantly based on self-reported information. Our aim was to examine the accuracy of self-reported vaccination status compared with official municipal records. Participants were women aged 20–22 yrs, who were attending for cervical screening in Niigata city. Among the 1230 eligible registrants, vaccine uptake, defined as any dose, was 75.0% and 77.2% according to a self-reported questionnaire and municipal records, respectively. The accuracy rate of self-reported information was as follows: positive predictive value (PPV) was 87.7%; negative predictive value (NPV) was 54.5%; sensitivity was 85.2%; and specificity was 59.8%. The validity of self-reported information was only moderate (Kappa statistic = 0.44, 95% confidence interval 0.37–0.50). This combined with the low NPV may lead to reduced estimation of effectiveness and safety. A more reliable method, such as a national HPV vaccine registry, needs to be established for assessing HPV immunization status in Japan.
       
  • HPV E6 oncoproteins and nucleic acids in neck lymph node fine needle
           aspirates and oral samples from patients with oropharyngeal squamous cell
           carcinoma

    • Abstract: Publication date: December 2018Source: Papillomavirus Research, Volume 6Author(s): M. Chernesky, D. Jang, J. Schweizer, M. Arias, L. Doerwald-Munoz, M. Gupta, B. Jackson, S. Archibald, J. Young, A. Lytwyn, M. Smieja, A. Severini, A. Ecobichon-Morris, M. HyrczaAbstractCommercial assays measuring HPV E6 viral oncoproteins, E6/E7 mRNA or DNA were used to test neck lymph node fine needle aspirates (FNA) and oropharyngeal samples (saliva and oral swabs) from 59 Canadian patients with oropharyngeal squamous cell carcinomas (OPSCC). Overall agreements of p16 antigen staining of tumors to FNA tested for OncoE6™, Aptima HPV E6/E7 mRNA and cobas HPV DNA were 81.4% (k 0.53), 94.9% (k 0.83) and 91.1% (k 0.73) respectively. Using HPV presence in a subset of 25 tumors as the comparator, overall agreement was 64.0% (k 0.08) with OncoE6™, 88.0% (k 0.65) with Aptima HPV E6/E7 mRNA and 91.7% (k 0.70) with cobas HPV DNA. HPV testing of oropharyngeal samples yielded lower agreements with tumor markers; 23.7–24.0% (k 0.02), 55.9–68.0% (k 0.24–0.37) and 78.9–86.9% (k 0.49–0.58) in the 3 respective tests. HPV 16 was present in 93.7–100% of the samples tested and showed 100% genotype agreement between FNA and tumors. The high rates for HPV E6 oncoproteins and E6/E7 mRNA suggests most patients were experiencing transcriptionally active HPV-related OPSCC. Results from these commercial assays performed on FNA but not oropharyngeal samples showed moderate to very good agreements with p16 and HPV testing of tumors.
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 3.215.182.81
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-